Knocking Out the Dopamine Reuptake Transporter (DAT) Does not Change the Baseline Brain Arachidonic Acid Signal in the Mouse

References

• Vial D, Piomelli D. Dopamine D2 receptors potentiate arachidonate release via activation of cytosolic, arachidonic-specific phospholipase A2. J Neurochem. 1995;64:2765–72.
   PubMedGoogle Scholar
• Ong WY, Sandhya TL, Horrocks LA, Farooqui AA. Distribution of cytoplasmic phospholipase A2 in the normal rat brain. J Hirnforsch. 1999;39:391–400.
   PubMedGoogle Scholar
• Rapoport SI. Arachidonic acid and the brain. J Nutr. 2008;138:2515–20.
   PubMed Web of Science ®Google Scholar
• Robinson PJ, Noronha J, Degeorge JJ, Freed LM, Nariai T, Rapoport SI. A quantitative method for measuring regional in vivo fatty-acid incorporation into and turnover within brain phospholipids: Review and critical analysis. Brain Res Brain Res Rev. 1992;17:187–214.
   PubMedGoogle Scholar
• Demar JC Jr, Ma K, Chang L, Bell JM, Rapoport SI. alpha-Linolenic acid does not contribute appreciably to docosahexaenoic acid within brain phospholipids of adult rats fed a diet enriched in docosahexaenoic acid. J Neurochem. 2005;94:1063–76.
   PubMed Web of Science ®Google Scholar
• Contreras MA, Chang MC, Kirkby D, Bell JM, Rapoport SI. Reduced palmitate turnover in brain phospholipids of pentobarbital-anesthetized rats. Neurochem Res. 1999;24:833–41.
   PubMedGoogle Scholar
• Saunders C, Ferrer JV, Shi L, Chen J, Merrill G, Lamb ME, Leeb-Lundberg LM, Carvelli L, Javitch JA, Galli A. Amphetamine-induced loss of human dopamine transporter activity: An internalization-dependent and cocaine-sensitive mechanism. Proc Natl Acad Sci USA. 2000;97:6850–55.
   PubMedGoogle Scholar
• Bhattacharjee AK, Chang L, Lee HJ, Bazinet RP, Seemann R, Rapoport SI. D2 but not D1 dopamine receptor stimulation augments brain signaling involving arachidonic acid in unanesthetized rats. Psychopharmacology (Berl). 2005;180: 735–42.
   PubMedGoogle Scholar
• Bhattacharjee AK, Chang L, White L, Bazinet RP, Rapoport SI. D-Amphetamine stimulates D2 dopamine receptor-mediated brain signaling involving arachidonic acid in unanesthetized rats. J Cereb Blood Flow Metab. 2006;26:1378–88.
   PubMedGoogle Scholar
• Bhattacharjee AK, Chang L, White L, Bazinet RP, Rapoport SI. Imaging apomorphine stimulation of brain arachidonic acid signaling via D2-like receptors in unanesthetized rats. Psychopharmacology (Berl). 2008;197:557–66.
   PubMedGoogle Scholar
• Basselin M, Chang L, Bell JM, Rapoport SI. Chronic lithium chloride administration to unanesthetized rats attenuates brain dopamine D2-like receptor-initiated signaling via arachidonic acid. Neuropsychopharmacology. 2005;30:1064–75.
   PubMedGoogle Scholar
• Bhattacharjee AK, Chang L, Chen M, White L, Bell JM, Bazinet RP, Rapoport SI. Chronic d-amphetamine depresses an imaging marker of arachidonic acid metabolism in rat brain. Int J Neuropsychopharmacol. 2008;11:1–13.
   Google Scholar
• Weiss F, Imperato A, Casu MA, Mascia MS, Gessa GL. Opposite effects of stress on dopamine release in the limbic system of drug-naive and chronically amphetamine-treated rats. Eur J Pharmacol. 1997;337:219–22.
   PubMedGoogle Scholar
• Robertson HA. Cerebral decortication reverses the effect of amphetamine on striatal D2 dopamine binding site density. Neurosci Lett. 1986;72:325–9.
   PubMedGoogle Scholar
• Shen HW, Hagino Y, Kobayashi H, Shinohara-Tanaka K, Ikeda K, Yamamoto H, Yamamoto T, Lesch KP, Murphy DL, Hall FS, Uhl GR, Sora I. Regional differences in extracellular dopamine and serotonin assessed by in vivo microdialysis in mice lacking dopamine and/or serotonin transporters. Neuropsychopharmacology. 2004;29:1790–9.
   PubMed Web of Science ®Google Scholar
• Giros B, Jaber M, Jones SR, Wightman RM, Caron MG. Hyperlocomotion and indifference to cocaine and amphetamine in mice lacking the dopamine transporter. Nature. 1996;379:606–12.
   PubMed Web of Science ®Google Scholar
• Jones SR, Gainetdinov RR, Jaber M, Giros B, Wightman RM, Caron MG. Profound neuronal plasticity in response to inactivation of the dopamine transporter. Proc Natl Acad Sci USA. 1998;95:4029–34.
   PubMed Web of Science ®Google Scholar
• Perona MT, Waters S, Hall FS, Sora I, Lesch KP, Murphy DL, Caron M, Uhl GR. Animal models of depression in dopamine, serotonin, and norepinephrine transporter knockout mice: Prominent effects of dopamine transporter deletions. Behav Pharmacol. 2008;19:566–74.
   PubMed Web of Science ®Google Scholar
• Gainetdinov RR, Jones SR, Caron MG. Functional hyperdopaminergia in dopamine transporter knock-out mice. Biol Psychiatry. 1999;46:303–11.
   PubMedGoogle Scholar
• Sora I, Wichems C, Takahashi N, Li XF, Zeng Z, Revay R, Lesch KP, Murphy DL, Uhl GR. Cocaine reward models: Conditioned place preference can be established in dopamine- and in serotonin-transporter knockout mice. Proc Natl Acad Sci USA. 1998;95:7699–704.
   PubMed Web of Science ®Google Scholar
• Basselin M, Villacreses NE, Langenbach R, Ma K, Bell JM, Rapoport SI. Resting and arecoline-stimulated brain metabolism and signaling involving arachidonic acid are altered in the cyclooxygenase-2 knockout mice. J Neurochem. 2006;96:669–79.
   PubMedGoogle Scholar
• Basselin M, Fox M, Chang L, Bell JM, Greenstein D, Chen M, Murphy DL, Rapoport SI. Imaging elevated brain arachidonic acid signaling in unanesthetized serotonin transporter (5-HTT)-deficient mice. Neuropsychopharmacology. 2009;34:1695–1709.
   PubMedGoogle Scholar
• Basselin M, Rosa AO, Ramadan E, Cheon Y, Chang L, Chen M, Greenstein D, Wohltmann M, Turk J, Rapoport SI. Imaging decreased brain docosahexaenoic acid metabolism and signaling in iPLA2beta (VIA)-deficient mice. J Lipid Res. 2010;51:3166–73.
   PubMedGoogle Scholar
• Basselin M, Kim HW, Chen M, Ma K, Rapoport SI, Murphy RC, Farias SE. Lithium modifies brain arachidonic and docosahexaenoic metabolism in rat lipopolysaccharide model of neuroinflammation. J Lipid Res. 2010;51: 1049–56.
   PubMedGoogle Scholar
• Basselin M, Ramadan E, Igarashi M, Chang L, Chen M, Kraft AD, Harry GJ, Rapoport SI. Imaging upregulated brain arachidonic acid metabolism in HIV-1 transgenic rats. J Cereb Blood Flow Metab. 2011;31:486–93.
   PubMedGoogle Scholar
• Folch J, Lees M, Sloane Stanley GH. A simple method for the isolation and purification of total lipides from animal tissues. J Biol Chem. 1957;226:497–509.
   PubMed Web of Science ®Google Scholar
• Franklin KBJ, Paxinos G. The mouse brain in stereotaxic coodinates. San Diego: Academic Press, Inc; 1997.
   Google Scholar
• Yang HC, Mosior M, Johnson CA, Chang L, Chen M, Kraft AD, Harry GJ, Rapoport SI. Group-specific assays that distinguish between the four major types of mammalian phospholipase A2. Anal Biochem. 1999;269:278–88.
   PubMed Web of Science ®Google Scholar
• Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976;72:248–54.
   PubMed Web of Science ®Google Scholar
• Levey AI, Hersch SM, Rye DB, Sunahara RK, Niznik HB, Kitt CA, Price DL, Maggio R, Brann MR, Ciliax BJ. Localization of D1 and D2 dopamine receptors in brain with subtype-specific antibodies. Proc Natl Acad Sci USA. 1993;90: 8861–5.
   PubMed Web of Science ®Google Scholar
• Alexander GE, Crutcher MD, Delong MR. Basal ganglia-thalamocortical circuits: Parallel substrates for motor, oculomotor, “prefrontal” and “limbic” functions. Prog Brain Res. 1990;85:119–46.
   PubMed Web of Science ®Google Scholar
• Yao WD, Gainetdinov RR, Arbuckle MI, Sotnikova TD, Cyr M, Beaulieu JM, Torres GE, Grant SG, Caron MG. Identification of PSD-95 as a regulator of dopamine-mediated synaptic and behavioral plasticity. Neuron. 2004;41:625–38.
   PubMed Web of Science ®Google Scholar
• Seeman P, Hall FS, Uhl G. Increased dopamine D2High receptors in knockouts of the dopamine transporter and the vesicular monoamine transporter may contribute to spontaneous hyperactivity and dopamine supersensitivity. Synapse. 2007;61:573–6.
   PubMedGoogle Scholar
• Fauchey V, Jaber M, Caron MG, Bloch B, Le Moine C. Differential regulation of the dopamine D1, D2 and D3 receptor gene expression and changes in the phenotype of the striatal neurons in mice lacking the dopamine transporter. Eur J Neurosci. 2000; 2:19–26.
   Google Scholar
• Jones SR, Gainetdinov RR, Hu XT, Cooper DC, Wightman RM, White FJ, Caron MG. Loss of autoreceptor functions in mice lacking the dopamine transporter. Nat Neurosci. 1999;2:649–55.
   PubMed Web of Science ®Google Scholar
• Gainetdinov RR, Wetsel WC, Jones SR, Levin ED, Jaber M, Caron MG. Role of serotonin in the paradoxical calming effect of psychostimulants on hyperactivity. Science. 1999;283:397–401.
   PubMed Web of Science ®Google Scholar
• Hayakawa T, Chang MC, Rapoport SI, Appel NM. Selective dopamine receptor stimulation differentially affects [3H]arachidonic acid incorporation, a surrogate marker for phospholipase A2-mediated neurotransmitter signal transduction, in a rodent model of Parkinson's disease. J Pharmacol Exp. Ther 2001;296:1074–84.
   PubMedGoogle Scholar
• Bhattacharjee AK, Meister LM, Chang L, Bazinet RP, White L, Rapoport SI. In vivo imaging of disturbed pre- and post-synaptic dopaminergic signaling via arachidonic acid in a rat model of Parkinson's disease. Neuroimage. 2007;37: 1112–21.
   PubMedGoogle Scholar
• Lee HJ, Rao JS, Ertley RN, Chang L, Rapoport SI, Bazinet RP. Chronic fluoxetine increases cytosolic phospholipase A2 activity and arachidonic acid turnover in brain phospholipids of the unanesthetized rat. Psychopharmacology (Berl). 2007;190:103–115.
   PubMedGoogle Scholar
• Parikh V, Apparsundaram S, Kozak R, Richards JB, Sarter M. Reduced expression and capacity of the striatal high-affinity choline transporter in hyperdopaminergic mice. Neuroscience. 2006;141:379–89.
   PubMedGoogle Scholar
• Morice E, Billard JM, Denis C, Mathieu F, Betancur C, Epelbaum J, Giros B, Nosten-Bertrand M. Parallel loss of hippocampal LTD and cognitive flexibility in a genetic model of hyperdopaminergia. Neuropsychopharmacology. 2007;32:2108–16.
   PubMed Web of Science ®Google Scholar
• Hall FS, Li XF, Sora I, Xu F, Caron M, Lesch KP, Murphy DL, Uhl GR. Cocaine mechanisms: Enhanced cocaine, fluoxetine and nisoxetine place preferences following monoamine transporter deletions. Neuroscience. 2002;115:153–61.
   PubMed Web of Science ®Google Scholar
• Barr AM, Lehmann-Masten V, Paulus M, Gainetdinov RR, Caron MG, Geyer MA. The selective serotonin-2A receptor antagonist M100907 reverses behavioral deficits in dopamine transporter knockout mice. Neuropsychopharmacology. 2004;29:221–8.
   PubMed Web of Science ®Google Scholar
• Rossetti ZL, Hmaidan Y, Gessa GL. Marked inhibition of mesolimbic dopamine release: A common feature of ethanol, morphine, cocaine and amphetamine abstinence in rats. Eur J Pharmacol. 1992;221:227–34.
   PubMed Web of Science ®Google Scholar
• Paulson PE, Robinson TE. Amphetamine-induced time-dependent sensitization of dopamine neurotransmission in the dorsal and ventral striatum: A microdialysis study in behaving rats. Synapse. 1995;19:56–65.
   PubMed Web of Science ®Google Scholar
• List SJ, Seeman P. [3H]dopamine labeling of D3 dopaminergic sites in human, rat, and calf brain. J Neurochem. 1982;39:1363–73.
   PubMedGoogle Scholar
• Seeman P, Schaus JM. Dopamine receptors labelled by [3H]quinpirole. Eur J Pharmacol. 1991;203:105–9.
   PubMedGoogle Scholar
• Seeman P, Tallerico T, Ko F, Tenn C, Kapur S. Amphetamine-sensitized animals show a marked increase in dopamine D2 high receptors occupied by endogenous dopamine, even in the absence of acute challenges. Synapse. 2002;46:235–9.
   PubMed Web of Science ®Google Scholar
• Jones SR, Gainetdinov RR, Wightman RM, Caron MG. Mechanisms of amphetamine action revealed in mice lacking the dopamine transporter. J Neurosci. 1998;18:1979–86.
   PubMed Web of Science ®Google Scholar
• Hesse S, Ballaschke O, Barthel H, Sabri O. Dopamine transporter imaging in adult patients with attention-deficit/hyperactivity disorder. Psychiatry Res. 2009;171:120–8.
   PubMedGoogle Scholar
• Kim CH, Cheon KA, Koo MS, Ryu YH, Lee JD, Chang JW, Lee HS. Dopamine transporter density in the basal ganglia in obsessive-compulsive disorder, measured with [123I]IPT SPECT before and after treatment with serotonin reuptake inhibitors. Neuropsychobiology. 2007;55:156–62.
   PubMed Web of Science ®Google Scholar
• Mathews TA, Fedele DE, Coppelli FM, Avila AM, Murphy DL, Andrews AM. Gene dose-dependent alterations in extraneuronal serotonin but not dopamine in mice with reduced serotonin transporter expression. J Neurosci Methods. 2004;140:169–81.
   PubMed Web of Science ®Google Scholar
• Sora I, Li B, Igari M, Hall FS, Ikeda K. Transgenic mice in the study of drug addiction and the effects of psychostimulant drugs. Ann N Y Acad Sci. 2010;1187:218–46.
   PubMedGoogle Scholar
• Li Q, Wichems CH, Ma L, Van de Kar LD, Garcia F, Murphy DL. Brain region-specific alterations of 5-HT2A and 5-HT2C receptors in serotonin transporter knockout mice. J Neurochem. 2003;84:1256–65.
   PubMedGoogle Scholar
• Qu Y, Chang L, Klaff J, Balbo A, Rapoport SI. Imaging brain phospholipase A2 activation in awake rat in response to 5-HT2A/2C agonist, (+−)-2,5-dimethoxy-4-iodophenyl-2-aminopropane (DOI). Neuropsychopharmacology. 2003;28:244–252.
   PubMedGoogle Scholar
• Giovacchini G, Lerner A, Toczek MT, Fraser C, Ma K, DeMar JC, Herscovitch P, Eckelman WC, Rapoport SI, Carson RE. Brain incorporation of [11C]arachidonic acid, blood volume, and blood flow in healthy aging: A study with partial-volume correction. J Nucl Med. 2004;45:1471–9.
   PubMedGoogle Scholar